Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion, Inc.
  6. News
  7. Summary
    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
End-of-day quote Korea Stock Exchange  -  2022-10-05
170000.00 KRW   -0.87%
09/28Celltrion's Oncology Drug Gets Marketing Authorization in Japan
MT
09/28S.Korean shares, won tumble on recession fears
RE
09/22Celltrion, Abpro Partner to Develop, Commercialize Breast Cancer Treatment Drug
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Infliximab Clinical Trial Updates

08/15/2022 | 02:13am EDT

The Big Molecule Watch is monitoring clinical trial activities involving infliximab. Here we report on recent studies with Celltrion's INFLECTRA (infliximab-dyyb).

Earlier this year, clinical trial data was published from an observational real-world study of patients with inflammatory bowel disease, including Crohn's disease ("CD") and ulcerative colitis ("UC") in the United States and Canada. A total of 67 CD and 48 UC patients were enrolled in the study. The study found that clinical outcomes among biologic-naďve users of Celltrion's infliximab-dyyb improved for UC and were maintained for CD patients. Similarly, biologic-naďve users of infliximab-dyyb showed significant improvements in patient reported outcomes.

More recently, results were published from a real-world post-marketing surveillance clinical study in Japan of 165 psoriasis patients treated with Celltrion's INFLECTRA (also known as CT-P13). According to the study, the response rate was high (78%) in patients with psoriatic arthritis, and 40% and 20% in those in plaque psoriasis and pustular psoriasis, respectively. Adverse drug reactions ("ADRs") occurred in 29 patients (17.6%), with infusion reaction reported as the most frequent ADR (6.7%). The study authors concluded that "CT-P13 showed excellent effectiveness as a first-line therapy, no clinical difficulties in switching from [IFX, the originator's infliximab], and usefulness in patients who failed other biologics," and that "CT-P13 could be a cost-effective alternative to IFX for the treatment of psoriasis."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

James Breen
Goodwin Procter LLP
The New York Times Building
620 Eighth Avenue
New York
NY 10018
UNITED STATES
Tel: 212813 8800
E-mail: JScalzi@goodwinlaw.com
URL: www.goodwinprocter.com

© Mondaq Ltd, 2022 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

All news about CELLTRION, INC.
09/28Celltrion's Oncology Drug Gets Marketing Authorization in Japan
MT
09/28S.Korean shares, won tumble on recession fears
RE
09/22Celltrion, Abpro Partner to Develop, Commercialize Breast Cancer Treatment Drug
MT
09/19Britain’s MHRA Clears Celltrion's Cancer Drug Vegzelma for Marketing in the UK
MT
09/06PTAB Institutes IPRs Of Tocilzumab Patents Challenged By Celltrion
AQ
09/05S.Korean shares end at over six-week low on Europe energy worries
RE
08/16Celltrion, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended Ju..
CI
08/15Infliximab Clinical Trial Updates
AQ
08/09Celltrion Files IND With FDA For Adalimumab Biosimilar
AQ
08/07Celltrion's Net Income Jumps 41.2% in June Quarter
MT
More news
Financials
Sales 2022 2 329 B 1,64 B 1,64 B
Net income 2022 620 B 0,44 B 0,44 B
Net cash 2022 746 B 0,52 B 0,52 B
P/E ratio 2022 38,3x
Yield 2022 0,27%
Capitalization 23 422 B 16 476 M 16 476 M
EV / Sales 2022 9,74x
EV / Sales 2023 8,74x
Nbr of Employees 2 034
Free-Float 74,8%
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 170 000,00 KRW
Average target price 221 000,00 KRW
Spread / Average Target 30,0%
EPS Revisions
Managers and Directors
Wu-Sung Ki Chief Executive Officer & Director
Ho-Seop Lee Finance Director
Jung-Jin Seo Chairman
Sung-Han Lee Head-Legal & Compliance Support
Dong-Il Kim Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CELLTRION, INC.-14.14%16 621
MODERNA, INC.-50.54%49 142
LONZA GROUP AG-33.72%38 001
IQVIA HOLDINGS INC.-31.78%35 901
SEAGEN INC.-11.47%25 244
ALNYLAM PHARMACEUTICALS, INC.18.67%24 128